Taylor Morrison Home
TMHC
Meritage Homes
MTH
D.R. Horton
DHI
Lennar Corp
LEN
Toll Brothers
TOL
US Stock MarketDetailed Quotes
ELTX Elicio Therapeutics
- 8.230
- -0.010-0.12%
Close Feb 25 16:00 ET
- 8.230
- 0.0000.00%
Post 16:00 ET
99.20MMarket Cap-1.89P/E (TTM)
8.890High7.990Low66.11KVolume8.140Open8.240Pre Close545.08KTurnover0.73%Turnover RatioLossP/E (Static)12.05MShares11.45052wk High-5.23P/B74.42MFloat Cap3.34252wk Low--Dividend TTM9.04MShs Float263.000Historical High--Div YieldTTM10.92%Amplitude2.960Historical Low8.245Avg Price1Lot Size
Elicio Therapeutics News
Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025
Elicio Shares Slide After Follow-On Offering Prices at Discount
Express News | Elicio Therapeutics Enters Definitive Securities Purchase Agreement With Institutional Investors For Purchase Of 1,261,830 Shares At $7.925
Express News | Elicio Therapeutics Inc - Offering Closing Expected on or About January 30, 2025
Express News | Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced at-the-Market Under Nasdaq Rules
Press Release: Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Elicio Therapeutics Advances With New Clinical Updates
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Elicio Therapeutics Gets FDA Support to Advance Cancer Immunotherapy, Plans Phase 3 Trial for ELI-002
Express News | Elicio Therapeutics: Phase 2 Randomized Study of Eli-002 Fully Enrolled, With Formal Interim Analysis of Disease-Free Survival Expected in H1 2025
Express News | Elicio Therapeutics Reaches Alignment With FDA on Eli-002 Registrational Strategy
Elicio Therapeutics Reaches Alignment With FDA on ELI-002 Registrational Strategy
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket
Elicio Therapeutics Presents Updated Results From ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment
Express News | Elicio Therapeutics Announces Completion of Phase 2 Amplify-7P Study Enrollment
Express News | Elicio Therapeutics Inc: Expects Current Cash and Cash Equivalents to Support Operations Into Q2 of 2025
Express News | Elicio Therapeutics Q3 2024 GAAP EPS $(1.39) Misses $(0.73) Estimate
Elicio Therapeutics Reports Q3 EPS ($1.39), Consensus (73c)
Elicio Therapeutics Files to Sell 3.44M Shares of Common Stock for Holders
Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.